Brief: Innate Pharma Q1 Revenues Down At EUR 4.5 Mln

Innate Pharma SA

11/05/2021 06:08

May 11 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * CASH POSITION OF EUR 181.7 MILLION¹ AS OF MARCH 31, 2021
    * LACUTAMAB TELLOMAK TRIAL PROGRESSES AS KIR3DL2-EXPRESSING
MYCOSIS FUNGOIDES COHORT ADVANCES TO STAGE 2 AFTER POSITIVE
EARLY SIGNAL
    * COMPANY'S FIRST NK CELL ENGAGER SELECTED BY SANOFI AS DRUG
CANDIDATE FOR DEVELOPMENT
    * REVENUES FOR FIRST THREE MONTHS OF 2021 AMOUNTED TO EUR
4.5
MILLION (EUR 19.3 MILLION FOR SAME PERIOD IN 2020)

Source text for Eikon:  ID:nGNX25ZNgR 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))